is now

Please update your bookmarks and favorites.
You will be taken to the new site in a few seconds.

Implementation Services

DermatologyGastroenterolgyUrologyHematologyTechnology

Our implementation process is the most robust and cost effective.

Inform Diagnostics has the experience your practice needs. You don't need to be the expert—we'll be your expert.

Preparation

Clients receive full-service system management, complete with a pre-configured, all-inclusive system backed by an Inform Diagnostics support team. Hardware is warrantied and customized to individual practices, and there is no need to train staff, or hire additional staff, to run IT. Inform Diagnostics implementation process allows you to focus on being a physician, taking time and stress away from grappling with equipment.

  • GAP analysis
  • Seamless interfaces
  • Paperless integration
  • Maximization your system and process efficiency
  • Customized content
  • Comprehensive reporting abilities

Implementation

Our expert team is deployed to your practice during and after installation to help prepare your staff. You will have a trusted person, familiar to your team and practice, providing a personalized training program and project management. Your bi-directional pathology interface is live on day 1, providing supplementary data, electronic results, and improved workflow, resulting in a more accurate, comprehensive diagnosis.

  • Assigned trainer throughout process
  • Customized training to meet your workflow needs
  • On-site training and access to materials
  • Dedicated Account Technical Manager

Support

Our goal is to empower you to operate your practice self-sufficiently, but Inform Diagnostics experts are never far away. For the first full week, a technician and trainer are on site, working side-by-side with your staff. Future updates? We have you covered. Our team upgrades, updates, and supports hardware and software.

  • On-site technician
  • Phone support
  • Dedicated Account Services Manager
  • Hardware upgrades
  • Update/upgrade management

Contact Inform Diagnostics to learn how we can assist your practice
Call 1.866.588.3280 or visit our Contact Page
.

Choose Inform Diagnostics for Your Patients


Learn more about Inform Diagnostics' pathology services

Learn More »

Miraca is so much more organized than any other lab. They’re really light years ahead of their competitors in quality and data.
— Dave Robbins, MD
Lenox Hill


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


January 8, 2018

Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

IRVING, Texas, January 8, 2018 — Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic capabilities that together help […]

Continue reading


November 20, 2017

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Continue reading


October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading


October 3, 2017

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered […]

Continue reading


September 22, 2017

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Continue reading